Iovance Biotherapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
23.00
|
|
Average Rating
|
4.27
|
|
# Strong Buys
|
8
|
|
# Buys
|
3
|
|
# Holds
|
4
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.64
|
-0.63
|
0.01
|
1.56%
|
|
2022-06-30
|
-0.61
|
-0.63
|
-0.02
|
-3.28%
|
|
2022-03-31
|
-0.64
|
-0.58
|
0.06
|
9.38%
|
|
2021-12-31
|
-0.56
|
-0.63
|
-0.07
|
-12.50%
|
|
2021-09-30
|
-0.53
|
-0.55
|
-0.02
|
-3.77%
|
|
2021-06-30
|
-0.51
|
-0.53
|
-0.02
|
-3.92%
|
|
2021-03-31
|
-0.49
|
-0.51
|
-0.02
|
-4.08%
|
|
2020-12-31
|
-0.44
|
-0.47
|
-0.03
|
-6.82%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.84
|
|
2021-12-31
|
-2.22
|
|
2020-12-31
|
-1.89
|
|
2019-12-31
|
-1.58
|
|
2018-12-31
|
-1.28
|
|
2017-12-31
|
-1.41
|
|
2016-12-31
|
-1.77
|
|
2015-12-31
|
-0.64
|
|
2014-12-31
|
-0.49
|
|
2013-12-31
|
-58.39
|
|
2012-12-31
|
-4.43
|
|
2011-12-31
|
-34.01
|
|
2010-12-31
|
-2.25
|
|
2009-12-31
|
0.00
|